SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING
February 02 2021 - 8:00AM
InvestorsHub NewsWire
SUNSHINE
BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION
EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033
Montreal, Canada -- February 2,
2021 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc.
(OTC PINK: "SBFM"),
a pharmaceutical company focused on the research, development and
commercialization of oncology and antiviral
drugs today
announced that it has received a "Notice of Allowance" from
the Canadian
Intellectual Property Office for a new patent application
covering Adva-27a, the Company's flagship
anticancer compound. This newly issued patent contains
new
subject matter and
extends the proprietary protection of
Adva-27a in
Canada until
2033. The equivalent
patent in
the United
States was
issued in 2019 (US Patent Number
10,272,065)
and
similarly covers Adva-27a until 2033. The
analogous
patents are still pending in Europe.
Sunshine Biopharma
is the sole owner of all intellectual property rights
pertaining to
Adva-27a, including the first Adva-27a patent
(US Patent
Number 8,236,935) issued in 2012.
"We are very excited about
this
significant
development for Adva-27a," said Dr. Steve N.
Slilaty, CEO
of Sunshine Biopharma. "Allowance of
this
patent
application
gives us
12
years of additional
protection and is a further validation of the
uniqueness and innovative aspects of
our
lead
anticancer
molecule," he added.
About
Sunshine Biopharma's
Adva-27a
Adva-27a is a unique anticancer compound
targeted for
multidrug resistant cancer. Tests conducted
to date
have demonstrated
the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada.
About
Sunshine Biopharma
In addition,
to working on the
development of Adva-27a, Sunshine Biopharma is engaged in the
development in the development of a
treatment COVID-19. Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over
2.1
million people
worldwide since it first appeared in December 2019. There are
currently no drugs that can effectively arrest replication of the
virus in people who have contracted the illness. On May 22, 2020,
Sunshine Biopharma filed a provisional patent application for
several molecules which were designed by computer-aided modeling to
inhibit the Coronavirus proteases, thus shutting down the ability
of the virus to multiply. Sunshine Biopharma has since completed
the synthesis of four such molecules and identified a lead compound,
SBFM-PL4. In collaboration with the University of Georgia,
College of Pharmacy, the Company is currently advancing the
development of SBFM-PL4 through the in vitro testing stage to be
followed by mice studies before entering clinical trials on
COVID-19 patients.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in
our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many
factors including but not limited to general stock market
conditions. Reference is hereby made to cautionary statements set
forth in the Company's most recent SEC filings. We have incurred
and will continue to incur significant expenses in our expansion of
our existing as well as new service lines noting there is no
assurance that we will generate enough revenues to offset those
costs in both the near and long term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma
Inc.
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com